Acyclovir–Dexamethasone Combination Therapy for Alzheimer’s Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease (AD) only alleviate symptoms and do not prevent or delay its progression, and the effectiveness of existing drugs like cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists is limited.
Innovation Solution
A combination therapy using acyclovir and dexamethasone (DXMT) is administered to treat AD, targeting neuroinflammation, synaptic protein expression, and cognitive impairment by inhibiting Aβ oligomers, reducing pro-inflammatory cytokines, and preserving PSD-95 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If cholinesterase inhibitors and NMDA receptor antagonists are used to treat AD, then cognitive symptoms are alleviated, but the disease progression cannot be prevented or delayed
Solution Approach 1:
The patent combines acyclovir and dexamethasone into a synergistic therapy regimen. Acyclovir targets HSV-1 replication while dexamethasone provides anti-inflammatory and immunomodulatory effects, creating a multi-mechanism approach that addresses both viral etiology and neuroinflammation, thereby achieving both symptom relief and disease progression prevention
Solution Approach 2:
The patent modifies the treatment approach by changing the pharmacological parameters from conventional single-drug therapy to a combination therapy with specific dosing ratios (acyclovir 5-10 mg/kg/day and dexamethasone 0.05-0.2 mg/kg/day). This parameter change enables simultaneous achievement of antiviral, anti-inflammatory, and neuroprotective effects that were not possible with single agents
2Reliability
If acyclovir is used alone to treat AD, then HSV-1 replication is inhibited, but weight loss and gastrointestinal side effects occur
Solution Approach 1:
Dexamethasone acts as an intermediary substance that mitigates the harmful effects of acyclovir. It provides glucocorticoid-mediated protection against acyclovir-induced weight loss and gastrointestinal irritation, allowing the antiviral therapy to be maintained at effective doses without excessive toxicity
Solution Approach 2:
The patent creates a composite therapeutic formulation combining acyclovir and dexamethasone in specific proportions. This composite approach integrates the antiviral properties of acyclovir with the protective and anti-inflammatory properties of dexamethasone, achieving a balanced therapeutic profile that maximizes benefit while minimizing harm
3Object-affected harmful factors
If dexamethasone is used alone to treat AD, then neuroinflammation is reduced, but cognitive impairment may be exacerbated
Solution Approach 1:
The patent segments the therapeutic function into two distinct components: acyclovir handles the antiviral and neuroprotective aspects, while dexamethasone handles the anti-inflammatory aspects. This segmentation allows each drug to operate at optimal doses for its specific function, with acyclovir counteracting the cognitive side effects of dexamethasone while dexamethasone amplifies the neuroprotective effects of acyclovir
4Reliability
If combination therapy with acyclovir and dexamethasone is used, then spatial cognitive impairment and neuroinflammation are improved, but treatment complexity increases
Solution Approach 1:
The patent demonstrates that the acyclovir-dexamethasone combination serves multiple functions simultaneously: antiviral activity, anti-inflammatory activity, neuroprotective activity, and cognitive protection. This multi-functionality justifies the treatment complexity by delivering multiple therapeutic benefits through a single combination regimen rather than requiring multiple separate therapies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of acyclovir and DXMT significantly alleviates spatial cognitive impairment, reduces neuroinflammation, and prevents Aβ oligomer-induced decreases in PSD-95 expression, offering a new therapeutic approach for AD.
Implementation Method 1
acyclovir could inhibit tryptophan-2,3-dioxygenase activity both in vitro and in vivo, leading to increases of serotonin and 5-hydroxyindole acetic acid levels
Implementation Method 2
Dexamethasone (DXMT), a synthetic glucocorticoid, is clinically used for treatment of allergic reactions and inflammatory skin conditions
Implementation Method 3
the acyclovir and the DXMT can also prevent Aβ oligomer-inducedhyperactivation of microglia and astrocytes, and overexpression of pro-inflammatory cytokines
Implementation Method 4
combined use of the acyclovir and the DXMT can block a Aβ oligomer-induced decrease of PSD95 expression, suggesting a protective effect of a drug combination on synapses
Data Source
Figure 1~3B
Figure 4A~4D
Figure 5A~5D
AI summary
The present disclosure provides use of a combination of acyclovir and dexamethasone (DXMT) in preparation of a drug for treating Alzheimer's disease (AD); where the use includes all symptoms of a patient with the AD, especially following symptoms: cognitive impairment and neuroinflammation. Combination of the acyclovir and the DXMT has a synergistic effect, to exert anti-inflammatory and immunoregulation effects to achieve an therapeutic effect.